Bullish
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham
Artiva Biotherapeutics is focusing on rheumatoid arthritis (RA) as the primary indication for its off-the-shelf NK cell therapy, expecting to release ...